Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Clinical Trials Using Carboplatin

Review the clinical trials studying carboplatin on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 226-250 of 267

NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Pembrolizumab in Combination with Chemotherapy and Image-Guided Surgery for the Treatment of Resectable Pleural Malignant Mesothelioma (MPM)
Status: Active
Location: University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania
Adding Tumor Treating Fields Therapy to Chemoradiation and Durvalumab for the Treatment of Patients with Locally Advanced Stage III Non-Small Cell Lung Cancer
Status: Active
Location: Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah
Chemoradiotherapy followed by Chemotherapy and Dostarlimab for the Treatment of Stage IIIC Endometrial Cancer
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Dupilumab, with Pembrolizumab, Paclitaxel, and Carboplatin for the Treatment of Locally Advanced Triple Negative Breast Cancer
Status: Active
Location: Icahn School of Medicine at Mount Sinai, New York, New York
Immunosensitizing Radiation with Neoadjuvant Chemoimmunotherapy for the Treatment of Patients with Stage II-IIIC Borderline Resectable Non-Small Cell Lung Cancer, The NeoRADjuvant Trial
Status: Active
Location: University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland
A Response-Guided Neoadjuvant Treatment Approach for Treating Stage Ib-III Stomach or Gastroesophageal Junction Cancer, RANT-GC Trial
Status: Active
Location: UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California
Mosunetuzumab in Combination with Platinum-Based Salvage Chemotherapy for the Treatment of Relapsed/Refractory Aggressive B Cell Lymphoma
Status: Active
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
Safety and Efficacy of Talactoferrin in Addition to Standard Chemotherapy in Patients With Non-small Cell Lung Cancer
Status: Active
Location: See ClinicalTrials.gov
REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
Status: Active
Location: See ClinicalTrials.gov
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
Status: Active
Location: See ClinicalTrials.gov
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Status: Active
Location: University of Wisconsin Carbone Cancer Center - University Hospital, Madison, Wisconsin
A Study to Compare the Combination of BMS-986504 With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
Status: Active
Location: See ClinicalTrials.gov
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Status: Active
Location: See ClinicalTrials.gov
Study Of Intraductal Carboplatin In Women With Ductal Carcinoma In Situ (DCIS)
Status: Active
Location: See ClinicalTrials.gov
Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL
Status: Active
Location: See ClinicalTrials.gov
Volrustomig Priming Regimens Exploratory Phase II Platform Study
Status: Active
Location: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)
Status: Active
Location: 2 locations
KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)
Status: Active
Location: 6 locations
Sacituzumab Tirumotecan (MK-2870) as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-2870-008)
Status: Active
Location: University of Florida Health Science Center - Gainesville, Gainesville, Florida
Debio 0123 in Combination With Carboplatin and Etoposide in Adult Participants With Small Cell Lung Cancer That Recurred or Progressed After Previous Standard Platinum-Based Therapy
Status: Active
Location: See ClinicalTrials.gov
FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery
Status: Active
Location: See ClinicalTrials.gov
Gemcitabine and Carboplatin for the Treatment of Locally Advanced or Metastatic, Progressive Urothelial Carcinoma
Status: Approved
Location: Fox Chase Cancer Center, Philadelphia, Pennsylvania